Process uses 3-D Printing to Produce Tough but Flexible Hydrogel Structures
Researchers have developed a new way of making tough — but soft and wet — biocompatible materials, called “hydrogels,” into complex and intricately patterned shapes. The process might lead to injectable materials for delivering drugs or cells into the body; scaffolds for regenerating load-bearing tissues; or tough but flexible actuators for future robots, the researchers say.
The new process is described in a paper in the journal Advanced Materials, co-authored by MIT associate professor of mechanical engineering Xuanhe Zhao and colleagues at MIT, Duke University, and Columbia University.
Zhao says the new process can produce complex hydrogel structures that are “extremely tough and robust,” and compatible with the encapsulation of cells in the structures. That could make it possible to 3D-print complex hydrogel structures; for example, implants to be infused with cells and drugs and then placed in the body.
Hydrogels, defined by water molecules encased in rubbery polymer networks that provide shape and structure, are similar to natural tissues such as cartilage, which is used by the body as a natural shock absorber. The new 3-D printing process could eventually make it possible to produce tough hydrogel structures artificially for repair or replacement of load-bearing tissues, such as cartilage.
While synthetic hydrogels are commonly weak or brittle, a number of them that are tough and stretchable have been developed over the last decade. However, previous ways of making tough hydrogels have usually involved “harsh chemical environments” that would kill living cells encapsulated in them, Zhao says.
The new materials are benign enough to synthesize together with living cells — such as stem cells — which could then allow high viability of the cells, says Zhao, who holds a joint appointment in MIT’s Department of Civil and Environmental Engineering.
In addition, the previous work was not able to produce complex 3-D structures with tough hydrogels, Zhao says. The new biocompatible tough hydrogel can be printed into diverse 3-D structures such as a hollow cube, hemisphere, pyramid, twisted bundle, multilayer mesh, or physiologically relevant shapes, such as a human nose or ear.
The new method uses a commercially available 3D-printing mechanism, Zhao explains. “The innovation is really about the material — a new ink for 3-D printing of biocompatible tough hydrogel,” he says — specifically, a composite of two different biopolymers. “Each [material] individually is very weak and brittle, but once you put them together, it becomes very tough and strong. It’s like steel-reinforced concrete.”
One of the two polymers provides elasticity to the printed material, while the other allows it to dissipate energy under deformation without breaking. A third ingredient, a biocompatible “nanoclay,” makes it possible to fine-tune the viscosity of the material, improving the ability to control its flow through the 3D-printing nozzle.
The material can be made so flexible that a printed shape, such as a pyramid, can be compressed by 99%, and then spring back to its original shape, Sungmin Hong, a lead author of the paper and a former postdoc in Zhao’s group, says; it can also be stretched to five times its original size. Such resilience is a key feature of natural bodily tissues that need to withstand a variety of forces and impacts.
Such materials might eventually be used to custom-print shapes for the replacement of cartilaginous tissues in ears, noses, or load-bearing joints, Zhao says. Lab tests have already shown that the material is even tougher than natural cartilage.
The next step in the research will be to improve the resolution of the printer, which is currently limited to details about 500 micrometers in size, and to test the printed hydrogel structures in animal models. “We are enhancing the resolution,” Zhao says, “to be able to print more accurate structures for applications.”
In addition to biomedical applications, the same technique could be applied to printing a variety of soft but tough structural materials, he says, such as actuators for soft robotic systems.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.